Advancing Peritoneal Dialysis (PD)
Millions of patients worldwide depend on dialysis to survive.
Our novel fluid, PDprotec®, is designed
to improve the outcomes of this treatment and
reduce the burden of kidney failure for patients and health care providers.
PDprotec® addresses the global market for
PD-fluids (USD 3 billion) and has the potential to increase
the share of PD in the overall dialysis market (USD 13 billion)
PDprotec® – key advantages

Improved clinical outcome

Prolonged time for which patients can benefit from PD

Increase market share of PD in dialysis overall
The Zytoprotec success story
Beginning of
Phase III
Study
> read more
- Product prepared to enter pivotal Phase III trial in 2021
- Outstanding safety and efficacy demonstrated for PDprotec® in Phase I/II and Phase II studies
- Orphan Drug designation granted by FDA
- Follow-on PD fluid ICOprotec™ ready for clinical development
Award-winning science
and world-class
clinical research
Science and Technology
The development of PDprotec® has been advanced by Zytoprotec’s own scientists and clinical experts and by the expertise and support provided by global leaders in the field of PD represented in our Scientific Advisory Board.
Scientific Advisory Board
A clear step forward in next generation PD solutions.
Prof. Dr. Nicholas Topley
They say a bit of stress is good for you – Zytoprotec research shows nicely how you can incorporate this principle into clinical practice of PD.
Prof. Dr. Janusz Witowski
An attractive approach to preserve the peritoneal membrane.
Prof. Dr. Manuel Lopez Cabrera